Welcome to our dedicated page for Quoin Pharmaceuticals SEC filings (Ticker: QNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Quoin Pharmaceuticals Ltd. (QNRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Quoin is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, and its filings offer detailed insight into clinical development plans, financing structures, governance decisions and risk factors relevant to investors.
Among the most informative documents for QNRX are its periodic reports and current reports on Form 8-K. Recent 8-K filings describe key events such as private placement financings involving American Depositary Shares, pre-funded warrants and multiple series of warrants tied to milestones for the lead asset, QRX003, including pivotal trial outcomes and potential FDA approval. Other 8-Ks outline regulatory milestones, including Orphan Drug Designation and Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome, as well as corporate actions like equity incentive plan approvals, changes in executive leadership and amendments to the company’s articles of association.
For users interested in the clinical and regulatory trajectory of Quoin’s programs, filings referenced to press releases detail the status of late-stage pivotal trials for QRX003, investigator-led pediatric studies and the development of topical rapamycin delivery technologies targeting microcystic lymphatic malformations and venous malformations. These documents also include the company’s cautionary statements about forward-looking information, highlighting uncertainties around clinical trial results, regulatory approvals, funding needs and operational risks.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that explain the significance of each filing in clear language. Users can quickly understand the core points of complex agreements, equity incentive plans, financing terms and clinical disclosures without reading every page of the original document. In addition, the filings page makes it easier to monitor governance items such as compensation policies, lock-up agreements and shareholder meeting results, all of which can influence the risk–reward profile of QNRX for market participants.
Quoin Pharmaceuticals Ltd. filed a Form 8-K describing a key regulatory step for its lead drug candidate QRX003, a late-stage topical treatment for the rare skin disorder Netherton Syndrome. The company has submitted an application to the Saudi Food and Drug Authority for Breakthrough Medicine Designation, a program intended to speed development, review and potential availability of medicines for serious conditions with high unmet need. Quoin believes QRX003 meets all SFDA eligibility criteria and states that, if the designation is granted, regulatory review could be accelerated and patient access in Saudi Arabia could begin as early as the second half of 2026. QRX003 already holds Orphan Drug and Pediatric Rare Disease designations from the U.S. FDA and Orphan Drug Designation from the European Medicines Agency. The drug is being tested in two late-stage pivotal whole-body clinical trials, with enrollment expected to complete in the first half of 2026 and top-line data anticipated in the second half of 2026. Subject to successful results, Quoin plans to submit a New Drug Application in the United States and other territories in late 2026 or early 2027. The company also reports that, as of January 20, 2026, it had 1,616,179 American Depositary Shares outstanding, each representing thirty-five ordinary shares.
Quoin Pharmaceuticals Ltd. is registering up to 10,045,455 American Depositary Shares (ADSs) for resale by investors who participated in an October 2025 private placement.
These ADSs include shares already issued and shares underlying pre-funded and ordinary warrants, and the company states that issuing all of them could significantly increase the ADSs in the public market. The ADSs covered by this prospectus that are not currently outstanding, including 1,968,939 Pre-Funded ADSs and 8,036,364 Ordinary Warrant ADSs, represent approximately 1,193% of the 838,976 ADSs outstanding as of November 3, 2025, so existing holders could experience substantial dilution.
Quoin will not receive proceeds from shareholder resales, but it could receive up to $88.7 million if all Ordinary Warrants are exercised for cash, which it plans to use for general corporate purposes, including advancing its rare-disease pipeline led by QRX003 for Netherton Syndrome and related orphan-designated programs.
Quoin Pharmaceuticals, Ltd. reported a new stock option grant to its Chief Financial Officer, Sally Bridget Lawlor, in a Form 4 filing. The grant covers an option to buy 10,330 American Depositary Shares (ADSs) at an exercise price of $19.36 per ADS, with each ADS representing thirty-five ordinary shares of Quoin. The option was approved by the company’s Compensation Committee on December 1, 2025 and expires on December 1, 2035.
The option vests over four years, with 20% of the ADSs vesting on each of December 1, 2026, 2027 and 2028, and the remaining 40% vesting on December 1, 2029. This filing reflects an equity-based component of the CFO’s compensation, designed to align her interests with long-term shareholder value.
Quoin Pharmaceuticals Ltd. reported that its Compensation Committee approved new standard forms of stock option award agreements for directors and executive officers under the company’s 2025 Equity Incentive Plan. These agreements are designed to allow a range of vesting schedules and terms within what the plan permits. If a grantee dies or becomes disabled, unvested options are forfeited, while vested options may be exercised for up to one year, subject to their stated expiration date. If a grantee is terminated for cause, all options, whether vested or unvested, are terminated and may be subject to recoupment by the company. For terminations for other reasons, unvested options are forfeited and vested options generally remain exercisable for up to three months, but not beyond their original expiration date.
Quoin Pharmaceuticals (QNRX) reported a technical milestone: it achieved the target loading concentrations for two topical rapamycin delivery technologies. The proprietary topical formulation reached a rapamycin loading concentration of 4% w/w, and a proprietary dermal patch system reached 5% w/w.
The company plans to begin manufacturing clinical trial and stability batches from at least one of these technologies this quarter, with the aim of commencing clinical testing in the first half of 2026. Initial clinical targets include Microcystic Lymphatic Malformations and Venous Malformations, areas where there are currently no FDA‑approved treatments or cures. The announcement was furnished under Regulation FD and includes forward‑looking statements subject to risks and uncertainties.
Quoin Pharmaceuticals Ltd. (QNRX) filed a Form S-3 to register the resale of up to 10,045,455 American Depositary Shares (ADSs) (representing 351,590,925 ordinary shares) by the selling shareholders, from time to time after effectiveness. The company is not offering these ADSs and will not receive proceeds from any resales.
Quoin notes it could receive up to $88.7 million only if the accompanying warrants are exercised for cash. The filing follows an October 2025 private placement that included Closing ADSs, Pre-Funded Warrants and Series H, I, J and K warrants. The company highlights potential dilution; the ADSs covered here (and not currently outstanding) are approximately 1,193% of ADSs outstanding as of the prospectus date.
As context, 838,976 ADSs were outstanding as of November 3, 2025. The registration fulfills contractual obligations under a registration rights agreement and allows selling holders to dispose of their ADSs via various permitted methods.
Quoin Pharmaceuticals (QNRX) reported Q3 2025 results with a net loss of $3.95 million as operating expenses rose to $4.02 million. Research and development climbed to $2.28 million (up ~111%) as the company advanced two pivotal QRX003 studies in Netherton Syndrome. As of September 30, cash and cash equivalents were $1.83 million and investments were $3.58 million.
Subsequent events strengthened liquidity: on October 10, Quoin closed a private placement for gross proceeds of approximately $16.6 million (about $15 million net) and later received $3.3 million from exercises of December 2024 warrants. Management concluded available resources are sufficient for at least one year after issuance of the financial statements. The FDA granted Orphan Drug Designation to QRX003 on October 21, 2025. Quoin previously regained Nasdaq minimum bid compliance in April 2025 following an ADS ratio change and reverse split.
Quoin Pharmaceuticals Ltd. furnished a Form 8-K announcing its third quarter financial results. The announcement was made on November 6, 2025, with a detailed press release attached as Exhibit 99.1.
The company stated that the information provided under Item 2.02 is not deemed “filed” for purposes of Section 18 of the Exchange Act and is incorporated by reference only as specified. Quoin’s American Depositary Shares trade on Nasdaq under the symbol QNRX, with each ADS representing thirty-five ordinary shares.
Quoin Pharmaceuticals (QNRX) announced that the FDA granted Orphan Drug Designation (ODD) to its lead candidate QRX003 for treating Netherton Syndrome. This follows ODD from the EMA in May 2025.
ODD provides benefits such as tax credits for qualified clinical testing, waiver or partial payment of FDA application fees, and seven years of U.S. market exclusivity if approved. QRX003 lotion (4%) is in two late‑stage, whole‑body pivotal trials.
Quoin expects enrollment in both pivotal studies to complete in the first quarter of 2026, with top‑line data in the second half of 2026, and an NDA submission planned later in the year.
Quoin Pharmaceuticals (QNRX) closed a private placement, raising approximately $16.6 million in upfront gross proceeds and about $15 million in net proceeds. The financing included ADSs, pre-funded warrants for ADSs, and four series of accompanying warrants, each permitting purchases of up to 2,009,091 ADSs.
The unit price for ADSs and accompanying warrants was $8.25, while pre-funded warrant units were priced at $8.2499. Director Dennis Langer participated, purchasing 15,152 ADSs with accompanying warrants for roughly $128,641 at $8.49. Warrants carry a 4.99% beneficial ownership cap; pre-funded warrants are exercisable at $0.0001 per ADS and allow cashless exercise. If a resale registration is not effective six months after issuance, the ordinary warrants may be exercised cashlessly.
Quoin agreed to file a resale registration within 30 days and target effectiveness within 60 days (or 90 days on full SEC review). The company placed 180‑day financing standstills and obtained 180‑day lock-ups from directors and officers. Potential future gross proceeds from warrant cash exercises total up to about $88.0 million.
FAQ
What is the current stock price of Quoin Pharmaceuticals (QNRX)?
What is the market cap of Quoin Pharmaceuticals (QNRX)?
